Astonea Labs Reports Robust H1 FY27 Results and Outlines Multi-Year Revenue Targets
Astonea Labs Ltd · Outcome · 14 Nov 2026, 9:27 pm
Astonea Labs Reports Robust H1 FY27 Results and Outlines Multi-Year Revenue Targets Astonea Labs reported strong H1 FY27 consolidated performance, with revenue rising 44.6% YoY to ₹95.86 crore, EBITDA surging 140.7% YoY to ₹13.20 crore (margin up 550 bps to 13.8%), and PAT jumping 153.3% YoY to ₹4.82 crore. Net working capital days improved to 107 days from 150 days YoY. The board approved acquiring a 51% stake in Longevity Science Pvt Ltd. Management guided for FY27 revenue exceeding ₹215 crore with 13–15% EBITDA margins, targeting ₹300 crore in FY28 and ₹405 crore in FY29.
Original exchange filing (PDF)
More announcements from Astonea Labs Ltd
- Non-Applicability of Statement of Deviation & Variation for the half year ended 30th September, 2026 · 15 Nov 2026
- Revised Outcome of Board Meeting held on 14th November, 2026 · 15 Nov 2026
- Unaudited Financial Results (Standalone & Consolidated) for the half year ended 30th September, 2026 · 14 Nov 2026
- Astonea Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve unaudited Standalone and Consolidated .... · 14 Nov 2026
- Please find enclosed herewith an Intimation regarding change in the Corporate Identification Number (CIN) of the Company consequent upon alteration of the Object Clause of the Memorandum .... · 09 Oct 2026
- Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 - Incorporation of Proposed Subsidiary- Longevity Science Private Limited · 08 Oct 2026
- Please find enclosed herewith re-submission of financial results for the half year and year ended 31.03.2025. · 22 Sept 2026
- Please find enclosed herewith resubmission of financial results for the financial year ended 31.03.2025, as the same was submitted in XBRL Version and as a part of outcome of the Board .... · 19 Sept 2026
